Table 6 Group comparison according to anxiety score between baseline and 12 months post-treatment
No anxiety (n=43) | Change to no anxiety (n=12) | Change to anxiety (n=14) | With anxiety (n=22) | p-value | |
|---|---|---|---|---|---|
Age | 30.0 [17.0, 58.0] | 34.0 [23.0, 61.0] | 29.5 [18.0, 55.0] | 27.0 [18.0, 48.0] | 0.335 |
Sex [Male] | 29 (67.4%) | 5 (41.7%) | 6 (42.9%) | 9 (40.9%) | 0.108 |
Heterozygous | 24 (55.8%) | 3 (25.0%) | 9 (64.3%) | 15 (68.2%) | 0.094 |
BMI (kg/m2) | 21.5 [16.2, 32.0] | 22.8 [19.2, 26.7] | 23.2 [18.3, 29.4] | 21.3 [18.1, 25.3] | 0.064 |
FEV1% | 63.0 [29.0, 108] | 66.5 [34.0, 105] | 62.5 [42.0, 93.0] | 66.5 [31.0, 114] | 0.950 |
Comorbility | |||||
Pancreatic insufficiency | 37 (86.0%) | 11 (91.7%) | 10 (71.4%) | 18 (81.8%) | 0.495 |
Hydrocarbon intolerance | 20 (46.5%) | 7 (58.3%) | 5 (35.7%) | 5 (22.7%) | 0.155 |
Hepatopathy | 11 (25.6%) | 4 (33.3%) | 4 (28.6%) | 3 (13.6%) | 0.557 |
Isolations | |||||
Pseudomonas aeruginosa | 19 (44.2%) | 3 (25.0%) | 5 (35.7%) | 8 (36.4%) | 0.659 |
Treatments | |||||
Previous Modulator | 20 (46.5%) | 7 (58.3%) | 4 (28.6%) | 7 (31.8%) | 0.302 |